Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

AstraZeneca Confident About Evusheld's Future Growth

As Next-Generation Version Moves Towards Clinic

Nov 11 2022

• By Kevin Grogan

AstraZeneca — • Source: Shutterstock: Elzbieta Krzysztof

Related Content

AstraZeneca To Remain In Vaccines For The Long Haul

Nov 10 2022

AZ’s Evusheld Receives World-First Approval As COVID-19 Treatment, In Japan

Aug 31 2022

AstraZeneca CTLA-4 Inhibitor Imjudo (Finally) Wins FDA Approval

Oct 24 2022

Anger Over Access To AstraZeneca's Evusheld Peaks In UK

Aug 15 2022

At Last, AZ’s Imfinzi/Tremelimumab Cancer Combo Shows Survival Benefit

May 07 2021

Evusheld: UK Urged To Use RWD To Give Clinically Vulnerable Early Access To COVID-19 Treatment

Sep 30 2022

Related Companies

AstraZeneca PLC

Additional Topics

Coronavirus COVID-19 Business Strategies Sales & Earnings Commercial Real-World Evidence BioPharmaceutical

More from COVID-19

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window